Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress

Core Insights - Evaxion A/S, a clinical-stage TechBio company, has developed novel vaccine design concepts for polio in collaboration with the Gates Foundation, utilizing its AI-Immunology™ platform [1][7] - The new polio vaccine concepts aim to combine the strengths of existing vaccines, addressing their shortcomings and enhancing the potential for polio eradication [2][3] - Evaxion will present these concepts at the World Vaccine Congress in Washington D.C. from March 31 to April 2, 2026 [1][6] Vaccine Development - Current polio vaccines are based on inactivated or attenuated virus versions, which have limitations in certain settings [2] - The AI-Immunology™ platform has enabled the development of hybrid capsid designs and de novo B-cell antigen approaches for the new polio vaccine [7][8] - Initial results from the new vaccine concepts support further development and potential collaboration opportunities [4] Additional Programs - Evaxion will also present data from its EVX-V1 program targeting Cytomegalovirus (CMV), which combines novel AI-discovered antigens with optimized versions of established CMV vaccine antigens [5][7] - The multi-targeted strategy of EVX-V1 is expected to enhance the protective potential of the future vaccine [5] Presentation Details - The presentation on the novel poliovirus vaccine will take place on April 1, 2026, at 16:40 ET, and will be led by Thomas Trolle, PhD [6] - An abstract on AI-powered target discovery for the CMV vaccine will be presented on April 2, 2026, at 10:25 ET by Pär Comstedt [6]